Tuberculosis cases associated with infliximab and etanercept [6]

Clinical Infectious Diseases

Volumn 39, Issue 8, 2004, Pages 1256-1257

  Winthrop, Kevin L ^a   Siegel, Jeffrey N ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; RISK FACTOR; THORAX RADIOGRAPHY; TUBERCULOSIS;

EID: 12844288622     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/424460     Document Type: Letter

References (6)

1. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-5.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345:1098-104.
3. Manadan AM, Mohan AK, Cote TR, Siegel JN, Sequeira W, Block JA. Tuberculosis and etanercept treatment [abstract]. Arthritis Rheum 2002; 46(Suppl9):S166.
4. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-47.
5. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:735-9.
6. Centers for Disease Control and Prevention. Tuberculosis associated with therapy against tumor necrosis factor-α antagonists, California 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:683-6.